Christopher Lau, MD
Orthopaedic Surgery · Honolulu, HINPI 1770927493
Payments from drug & device makers
What this record shows
This record is dominated by education: $9,157 of the $14,044 with a category attached, or 65.2%. 9 manufacturers reported payments, led by Arthrex at 55.5% of the total. Reporting peaked in 2019 at $10,814 and has fallen 99.6% since, to $39 in 2025.
Across 57 payments — averaging $246.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$8K
- Smith+Nephew$5K
- Actelion Pharmaceuticals US, Inc.$348
- Stryker$331
- Bioventus LLC$278
- Impactortho, Inc.$166
- plus $85 from 3 others
What the payments were for
- Travel & lodging$1,81613%
- Food & beverage$3,07122%
- Education$9,15765%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 34 | $7,799 |
| Smith+Nephew | 4 | $5,036 |
| Actelion Pharmaceuticals US, Inc. | 3 | $348 |
| Stryker | 2 | $331 |
| Bioventus LLC | 9 | $278 |
| Impactortho, Inc. | 2 | $166 |
| Elevate Surgical Co | 1 | $37 |
| Vericel Corporation | 1 | $29 |
| Johnson & Johnson | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REUNION$166
- NA$165
- Journey II BCS$150
- POLARSTEM$150
- OPSUMIT$124
- UPTRAVI$124
- BIOLOGICS CONSUMABLES BONE REPAIR CELLULAR BONE GRAFTING KIT$123
How this compares
$14,044 in reported general payments places this provider in the 75th percentile of 83 orthopaedic surgery providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 16 | $221 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 17 | $106 |
| Tramadol Hcl | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Honolulu
- Cass NakasoneHonolulu$957K
- Darin AwayaHonolulu$445K
- Christian KikuchiHonolulu$142K
- Paul MortonHonolulu$83K
- Gary OkamuraHonolulu$69K
- Andrew RichardsonHonolulu$55K
- Kyle MitsunagaHonolulu$52K
- Kanu OkikeHonolulu$47K
- Brian ManninoHonolulu$43K
- Morris MitsunagaHonolulu$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.